Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AADI NYSE:ATNM NASDAQ:CEMI NASDAQ:ELYM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAADIAadi Bioscience$2.02-6.9%$1.85$1.21▼$3.81$49.89M0.68261,100 shs46,042 shsATNMActinium Pharmaceuticals$1.56-3.1%$1.63$1.03▼$2.41$48.67M-0.25363,806 shs191,858 shsCEMIChembio Diagnostics$0.46$0.43$0.19▼$1.24$16.71M1.85661,416 shs351,642 shsELYMEliem Therapeutics$2.00+11.1%$2.08$2.35▼$11.55$59.50M-0.39486,688 shs600,177 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAADIAadi Bioscience0.00%-6.05%+1.51%+4.12%-6.05%ATNMActinium Pharmaceuticals-3.11%-1.27%-4.29%-1.89%-12.36%CEMIChembio Diagnostics0.00%0.00%0.00%0.00%0.00%ELYMEliem Therapeutics+11.11%+10.50%-11.11%+45.99%-63.24%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAADIAadi Bioscience$2.02-6.9%$1.85$1.21▼$3.81$49.89M0.68261,100 shs46,042 shsATNMActinium Pharmaceuticals$1.56-3.1%$1.63$1.03▼$2.41$48.67M-0.25363,806 shs191,858 shsCEMIChembio Diagnostics$0.46$0.43$0.19▼$1.24$16.71M1.85661,416 shs351,642 shsELYMEliem Therapeutics$2.00+11.1%$2.08$2.35▼$11.55$59.50M-0.39486,688 shs600,177 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAADIAadi Bioscience0.00%-6.05%+1.51%+4.12%-6.05%ATNMActinium Pharmaceuticals-3.11%-1.27%-4.29%-1.89%-12.36%CEMIChembio Diagnostics0.00%0.00%0.00%0.00%0.00%ELYMEliem Therapeutics+11.11%+10.50%-11.11%+45.99%-63.24%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAADIAadi Bioscience 0.00N/AN/AN/AATNMActinium Pharmaceuticals 3.00Buy$4.50188.46% UpsideCEMIChembio Diagnostics 0.00N/AN/AN/AELYMEliem Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAADIAadi Bioscience$25.07M1.99N/AN/A$4.29 per share0.47ATNMActinium PharmaceuticalsN/AN/AN/AN/A$1.31 per shareN/ACEMIChembio Diagnostics$48.34M0.35N/AN/A$0.48 per share0.95ELYMEliem TherapeuticsN/AN/AN/AN/A$3.90 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAADIAadi Bioscience-$65.76M-$2.35N/AN/AN/A-246.06%-71.87%-57.28%11/4/2025 (Estimated)ATNMActinium Pharmaceuticals-$48.82M-$1.31N/AN/AN/AN/A-100.85%-47.89%N/ACEMIChembio Diagnostics-$23.29M-$1.20N/A∞N/A-47.03%-113.57%-38.22%N/AELYMEliem Therapeutics-$35.12M-$0.53N/A∞N/AN/A-47.03%-45.97%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAADIAadi BioscienceN/AN/AN/AN/AN/AATNMActinium PharmaceuticalsN/AN/AN/AN/AN/ACEMIChembio DiagnosticsN/AN/AN/AN/AN/AELYMEliem TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAADIAadi BioscienceN/A4.894.54ATNMActinium PharmaceuticalsN/A10.2510.25CEMIChembio DiagnosticsN/A1.231.04ELYMEliem TherapeuticsN/A60.4160.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAADIAadi Bioscience52.08%ATNMActinium Pharmaceuticals27.50%CEMIChembio Diagnostics8.65%ELYMEliem Therapeutics69.76%Insider OwnershipCompanyInsider OwnershipAADIAadi Bioscience37.30%ATNMActinium Pharmaceuticals6.00%CEMIChembio Diagnostics3.30%ELYMEliem Therapeutics4.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAADIAadi Bioscience4024.70 million15.49 millionOptionableATNMActinium Pharmaceuticals3031.20 million29.32 millionOptionableCEMIChembio Diagnostics33736.73 million35.51 millionNot OptionableELYMEliem Therapeutics929.75 million28.35 millionNot OptionableCEMI, AADI, ELYM, and ATNM HeadlinesRecent News About These CompaniesEliem Therapeutics (NASDAQ:ELYM) Shares Down 2.9% - Time to Sell?October 7, 2025 | marketbeat.comEliem Therapeutics (NASDAQ:ELYM) Trading Up 0.8% - Here's WhySeptember 15, 2025 | marketbeat.comClimb Bio Reports Increased Losses Amid Ongoing DevelopmentMay 15, 2025 | tipranks.comWhiteSwell has positive fluid removal dataFebruary 13, 2025 | massdevice.comClimb Bio ascends from Eliem legacy with $9M upfront deal for preclinical IgA antibodyJanuary 9, 2025 | fiercebiotech.comFEliem Therapeutics (NASDAQ:ELYM) Stock, Short Interest ReportOctober 9, 2024 | benzinga.comEliem Therapeutics mounts corporate rebrand after pipeline overhaul, mass layoffsOctober 4, 2024 | fiercepharma.comFEliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.October 2, 2024 | globenewswire.comEliem Therapeutics Inc (ELYM) Stock: Surpassing Expectations in the Market?October 2, 2024 | bovnews.comBWhy Did Eliem Therapeutics Inc (ELYM) Stock Plunge -40.93% Last Week?September 28, 2024 | bovnews.comBEliem Therapeutics Inc’s Stock Drama: Could This Be a Game-Changer for ELYM Investors?September 26, 2024 | bovnews.comBTrading (ELYM) With Integrated Risk ControlsSeptember 24, 2024 | news.stocktradersdaily.comNEliem Therapeutics: Recent Strategic Pipeline RestructuringSeptember 23, 2024 | seekingalpha.comEliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation SummitSeptember 11, 2024 | globenewswire.comEliem Therapeutics Inc (ELYM) Stock Trading RecapSeptember 11, 2024 | bovnews.comBEliem Therapeutics Inc (ELYM) Stock: More Resilient Than It AppearsSeptember 2, 2024 | bovnews.comBEliem Therapeutics Announces Additions to its Leadership TeamAugust 26, 2024 | globenewswire.com(ELYM) Long Term Investment AnalysisAugust 18, 2024 | news.stocktradersdaily.comNEliem Therapeutics Reports Second Quarter Financial ResultsAugust 14, 2024 | globenewswire.comWhere are the Opportunities in (ELYM)July 27, 2024 | news.stocktradersdaily.comNEliem Therapeutics, Inc. (NASDAQ:ELYM) EVP Valerie Morisset Sells 69,005 SharesJuly 24, 2024 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCEMI, AADI, ELYM, and ATNM Company DescriptionsAadi Bioscience NASDAQ:AADI$2.02 -0.15 (-6.91%) As of 10/10/2025Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.Actinium Pharmaceuticals NYSE:ATNM$1.56 -0.05 (-3.11%) Closing price 10/14/2025 04:00 PM EasternExtended Trading$1.56 +0.00 (+0.32%) As of 10/14/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.Chembio Diagnostics NASDAQ:CEMIChembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Medford, NY.Eliem Therapeutics NASDAQ:ELYM$2.00 +0.20 (+11.11%) As of 10/13/2025Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Healthcare Companies Insiders Are Buying NVIDIA Analysts Lift Targets: What It Means for the Stock Price Fastenal Stock Pulls Back in October—Is It Time to Buy FAST? 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Why Congress Is Buying Intuitive Surgical Ahead of Earnings D-Wave: Reevaluating the Short Seller’s Case After the Downgrade 3 Dividend Hikes That Signal Renewed Strength in 2025 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
